RMW Cho Group Limited is pleased to announce that following extensive research and development efforts, it has selected a new Active Pharmaceutical Ingredient (API) to progress with.

Provisional patents relating to the new API, called INV-043, have been filed and initial tests carried out by Hudson Institute of Medical Research, indicate that INV-043 has greater anti-cancer activity and better cancer-targeting characteristics than previous generations of APIs.

Key points

• New API (INV-043) selected to advance research and development (R&D) on next-generation of Photodynamic Therapy (PDT) cancer treatments
• Early indications from Hudson Institute show INV-043 to have superior anti-cancer activity and cancer-targeting characteristics
• Provisional patents have been filed
• Results from initial proof-of-concept models on T-cell lymphoma, triple negative breast and pancreatic cancers are being finalised and will be released in the coming weeks
• Work is commencing on additional proof-of-concept studies using INV-043 on immunocompetent in vivo models
• The results from these proof-of-concept models will help shape the R&D program, timelines and target indications

Hudson Institute is finalising work on initial proof-of-concept models testing ablation in three cancer types; triple negative breast cancer, T-cell lymphoma and pancreatic cancer.

Further, Hudson Institute is commencing additional proof-of-concept work with INV-043 on immunocompetent in vivo models.

About RMW Cho Group Limited

RMW Cho Group Limited funds and develops advanced technology Humanitarian and Environmental projects combining an ethical business model with highly profitable businesses. Research and clinical trials using PhotosoftTM technology are funded by the technology licensor, RMW Cho Group Limited, via an R&D services agreement with the Company.

About Photodynamic Therapy (PDT)

PhotosoftTM technology as an improved next generation Photodynamic Therapy. PDT uses non-toxic photosensitisers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen that kills malignant cells, shuts down tumours and stimulates the immune system. A potential alternative to surgery, and in contrast to radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumour by leukocytes.